S&P Capital IQ Initiates Coverage on Pressure BioSciences, Inc. in S&P Capital IQ Factual Stock Reports

NEW YORK, Dec. 17, 2014 /PRNewswire/ -- S&P Capital IQ (MHFI) announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Pressure BioSciences Inc. (OTCQB: PBIO).

Pressure BioSciences, Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Through mid-November 2014, the company had installed over 250 pressure cycling technology systems in approximately 160 sites worldwide.

Pressure BioSciences has developed and currently has 24 issued patents covering a novel, enabling technology platform that can accurately control the sample preparation process to assist scientists working in biological life sciences research. The company's technology platform is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, i.e., 35,000 pounds per square inch (psi) or greater, to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. The company notes that sample preparation is often complex, time-consuming and, in its belief, one of the most error-prone steps of scientific research.

The company's pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, lipids and small molecules. The company's laboratory instrument, the Barocycler, and its internally developed consumables product line, which include its Pressure Used to Lyse Samples for Extraction (PULSE) tubes, and other processing tubes, and application-specific kits such as consumable products and reagents, together make up the company's PCT Sample Preparation System (PCT SPS).

Pressure BioSciences is also the exclusive distributor throughout the Americas for the Constant Systems cell disruption equipment, parts and consumables. Constant Systems, Ltd (CS), a British company, has been providing niche biomedical equipment, related consumable products and services to a global client base since 1989. CS designs, develops and manufactures high pressure cell disruption equipment required by life sciences laboratories worldwide, particularly disruption systems for the extraction of proteins. The CS equipment provides a constant and controlled cell disruptive environment. The CS cell disruption equipment is used in the extraction of cellular components, such as protein from yeast, bacteria, mammalian cells and other sample types.

According to Pressure BioSciences, the CS pressure-based cell disruption equipment and the company's PCT instrumentation complement each other in several important ways. While both the CS and Pressure BioSciences technologies are based on high pressure, each product line has fundamental scientific capabilities that the other does not offer. The company's PCT platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects. CS's technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing. In a number of routine laboratory applications, such as protein extraction, both effects can be critical to success, the company believes. Therefore, for protein extraction and a number of other important scientific applications, Pressure BioSciences believes that laboratories will benefit by using the CS and Pressure BioSciences products, either separately or together.

In September 2014, the company announced that it had successfully completed the first phase of its commercialization plan for its recently released high-throughput, PCT-based instrument system, the Barozyme HT48. The new Barozyme HT48 system was designed to integrate well with current standardized, high-throughput, liquid-handling laboratory automation and robotics installed in tens of thousands of biological research laboratories worldwide.

Pressure BioSciences, Inc. was founded in 1978 as Boston Biomedica, which became one of the world leaders in developing and selling quality control products to help ensure the accuracy of infectious disease testing for blood borne pathogens such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Boston Biomedica, a company of over 300 persons worldwide, was disbanded in 2004, and the remaining company consisted of Mr. Schumacher and three others. Subsequently, Mr. Schumacher changed the name to Pressure BioSciences,changed the core competency from infectious disease quality control diagnostics to a company of life sciences tools and services, and began to build the infrastructure that the company has today.

S&P Capital IQ's Factual Stock Report coverage on Pressure BioSciences Inc. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.pressurebiosciences.com for additional information.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.      

About S&P Capital IQ's Factual Stock Reports

Currently profiling approximately 400 issuers, S&P Capital IQ (MHFI) Factual Stock Reports increase market awareness of issuers in the investment community with insightful commentary, key statistics, and relevant corporate information.  The Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information on the covered companies to reach a wide spectrum of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the Reports also capture recent company developments, a financial review, key operating information, industry and peer comparisons, Street Consensus, performance charts, business summary, fundamental data, and timely news stories. Coverage of these reports is underwritten by the issuer, therefore S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

S&P Capital IQ Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations.  S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial (NYSE:MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need.  For more information, visit www.spcapitaliq.com.

In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sp-capital-iq-initiates-coverage-on-pressure-biosciences-inc-in-sp-capital-iq-factual-stock-reports-300011199.html

SOURCE S&P Capital IQ

Related Links

http://www.spcapitaliq.com